Healthcare Equipment and Supplies
Company Overview of Aspire Bariatrics, Inc.
Aspire Bariatrics, Inc. develops and commercializes weight loss solutions for customers in Europe and internationally. It offers AspireAssist, a weight loss solution for people with obesity. Its AspireAssist works by reducing the calories absorbed by the body. Aspire Bariatrics, Inc. was formerly known as Aspiration Medical Technology, LLC. The company was incorporated in 2004 and is based in King Of Prussia, Pennsylvania.
3200 Horizon Drive
King of Prussia, PA 19406
Founded in 2004
Key Executives for Aspire Bariatrics, Inc.
Chairman of The Board, Chief Executive Officer and President
Executive Vice President of Sales, Marketing and Clinical Support
Compensation as of Fiscal Year 2015.
Aspire Bariatrics, Inc. Key Developments
Aspire Bariatrics Inc. Secures $12 Million Venture Loan Facility with Hercules Technology Growth Capital
Jan 29 15
Aspire Bariatrics Inc. announced that it has closed on up to $12 million in venture debt financing with Hercules Technology Growth Capital. The financing will support the continuation of the company's PATHWAY pivotal trial in the US and Pre-Market Application filing, expected in mid-2015. The financing will also support ongoing post-market studies for the device, which is currently approved for commercial sale in Europe.
Aspire Bariatrics, Inc. Announces Completion of Enrollment & Device Implantation in Pivotal US Trial
Jul 8 14
Aspire Bariatrics, Inc. announced that it has completed enrollment and device implantation in the company's PATHWAY pivotal trial for obesity as of June 18, 2014. A total of 171 patients have been enrolled at 10 clinical sites in the United States. The PATHWAY trial is a randomized, controlled, pivotal study testing the effectiveness and safety of the AspireAssist Aspiration Therapy System in the treatment of obesity in patients with initial body mass index from 35.0-55.0 kg/m. The AspireAssist is a first in class chronic weight loss treatment which is designed to reduce caloric absorption while gradually changing eating habits. The device does not alter the patient's gastrointestinal anatomy, is minimally invasive, and is easily reversible. The company also announced the initiation of post-market studies in Italy, United Kingdom, Austria, and Germany, in addition to ongoing post-market studies in Sweden, Czech Republic, and Spain.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 29, 2015
Most Searched Private Companies
Sponsored Financial Commentaries